Context Therapeutics Inc (CNTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $16.61M
Last updated: Nov 17, 2026 at 11:04 AM ET
Context Therapeutics Inc (CNTX) Competitors
The companies most similar to Context Therapeutics are Transcode Therapeutics (RNAZ), Cyclerion Therapeutics (CYCN) and Plus Therapeutics (PSTV). By market cap, Context Therapeutics ranks 7th of the 13 companies on this page; Quince Therapeutics (QNCX) is the largest at $32.27M.
Peer Comparison
CNTX's revenue growth of 0.0% is above the peer median of -1.4%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Context Therapeutics (CNTX) | $16.61M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Transcode Therapeutics Inc (RNAZ) | $22.35M | N/A | N/A | 0.0% | -412.7% | 0.0% | 0.00% |
| Cyclerion Therapeutics Inc (CYCN) | $15.73M | N/A | N/A | 0.0% | N/A | -43.2% | 0.00% |
| Plus Therapeutics Inc (PSTV) | $26.64M | N/A | 2.0x | -230.2% | -827.8% | -2.9% | 0.00% |
| Tscan Therapeutics Inc (TCRX) | $10.89M | N/A | 3.6x | 0.0% | -129.7% | -65.8% | 0.00% |
| Citius Pharmaceuticals Inc (CTXR) | $14.69M | N/A | 1.9x | 0.0% | -84.3% | 0.0% | 0.00% |
| Quoin Pharmaceuticals Ltd DRC (QNRX) | $17.78M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| NextCure Inc (NXTC) | $29.31M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Marker Therapeutics Inc (MRKR) | $14.51M | N/A | 14.5x | -245.5% | N/A | -51.0% | 0.00% |
| Cocrystal Pharma Inc (COCP) | $18.88M | N/A | 39.2x | 0.0% | N/A | 26.9% | 0.00% |
| Akari Therapeutics PLC (AKTX) | $15.54M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Fractyl Health, Inc. Common Stock (GUTS) | $11.99M | N/A | N/A | 0.0% | -245.8% | -57.1% | 0.00% |
| Quince Therapeutics, Inc. (QNCX) | $32.27M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $16.75M | N/A | 3.6x | 0.0% | -245.8% | -1.4% | 0.00% |
Similar Companies
These are the 12 companies most similar to Context Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Transcode Therapeutics Inc (RNAZ) | TransCode Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development and commercialization of drugs for the treatment of metastatic... | RNAZ competitors |
| Cyclerion Therapeutics Inc (CYCN) | Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development... | |
| Plus Therapeutics Inc (PSTV) | Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacturing... | PSTV competitors |
| Tscan Therapeutics Inc (TCRX) | Tscan Therapeutics Inc (TCRX) is a pioneering clinical-stage biotechnology company specializing in precision oncology through its proprietary T cell receptor... | TCRX competitors |
| Citius Pharmaceuticals Inc (CTXR) | Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets critical care products. | CTXR competitors |
| Quoin Pharmaceuticals Ltd DRC (QNRX) | Quoin Pharmaceuticals Ltd (QNRX) is an innovative biotechnology firm dedicated to developing cutting-edge therapeutics for rare diseases... | QNRX competitors |
| NextCure Inc (NXTC) | NextCure, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of novel immunomedicines to treat cancer and other... | NXTC competitors |
| Marker Therapeutics Inc (MRKR) | Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based... | MRKR competitors |
| Cocrystal Pharma Inc (COCP) | Cocrystal Pharma, Inc., a biotechnology company, is focused on the discovery and development of antiviral therapeutic treatments for serious and / or chronic... | COCP competitors |
| Akari Therapeutics PLC (AKTX) | Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory... | AKTX competitors |
| Fractyl Health, Inc. Common Stock (GUTS) | Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. | GUTS competitors |
| Quince Therapeutics, Inc. (QNCX) | Quince Therapeutics, Inc., a biopharmaceutical company, is focused on advancing precision therapies for rare and debilitating diseases. |
Frequently Asked Questions About CNTX
Who are Context Therapeutics' main competitors?
The companies most similar to Context Therapeutics include Transcode Therapeutics (RNAZ), Cyclerion Therapeutics (CYCN), Plus Therapeutics (PSTV), Tscan Therapeutics (TCRX) and Citius Pharmaceuticals (CTXR), listed from the closest match.
Who is Context Therapeutics' biggest competitor?
Quince Therapeutics (QNCX) is the largest of the similar companies at $32.27M; Transcode Therapeutics (RNAZ) is the closest match by business profile, size, sector and industry.
How does CNTX stock compare with its competitors?
CNTX's net margin is 0.0% against a peer median of 0.0%.
Which of Context Therapeutics' competitors pays a higher dividend?
Context Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Context Therapeutics bigger than its competitors?
No. Context Therapeutics is 7th by market cap among the 13 companies on this page; the largest is Quince Therapeutics (QNCX) at $32.27M.
CNTX pages: Overview, Earnings, Forecast, Financials, Competitors